Introduction
============

Liver cancer is the third leading cause of cancer death in China, with an age-standardized 5-year relative survival rate of 10.1%.[@b1-cmar-10-953],[@b2-cmar-10-953] The majority of liver cancer cases are hepatocellular carcinoma (HCC).[@b3-cmar-10-953] A high prevalence of hepatitis B virus (HBV) infection and aflatoxin B1 exposure are the main factors of HCC in the Guangxi province of China.[@b4-cmar-10-953]--[@b6-cmar-10-953] Previous studies have demonstrated that the tumor protein p53 (*TP53*) mutation is frequently found in HBV-related HCC in patients of Guangxi province.[@b7-cmar-10-953]--[@b10-cmar-10-953] Therefore, in the Guangxi region, there is a representative population in which the associations between HBV infection and the *TP53* gene in HCC can be investigated.

Hepatocarcinogenesis is driven by the interaction of genetic and environmental factors.[@b11-cmar-10-953],[@b12-cmar-10-953] Genome-wide association studies (GWAS) can be used to identify associations between specific single nucleotide polymorphisms (SNPs) and complex diseases or other traits.[@b13-cmar-10-953] The roles of the corresponding genes or proteins in the context of the pathway might be altered by trait-related SNPs. Identify candidate Causal SNPs and Pathways (ICSNPathway) is an analytical framework for the comprehensive interpretation of GWAS data by integrating linkage disequilibrium (LD) analysis, functional SNP annotation, and pathway-based analysis (PBA) and can be used to derive the mechanism hypothesis of SNP→gene→pathway(s) for complex disease studies, including cancer.[@b14-cmar-10-953] In addition, ICSNPathway also is a tool based on PBA algorithm, which is a method for secondary excavation of GWAS results based on prior biological knowledge on gene function and biological metabolic pathways.[@b14-cmar-10-953] By using the PBA algorithm, more information about the pathway and gene sets with same functions which are associated with the diseases or traits from GWAS results could be obtained.

Our previous study has identified several SNPs associated with TP53 expression status in HBV-related HCC in patients of Guangxi by using the GWAS approach.[@b15-cmar-10-953] In the present study, we further investigated candidate SNPs and molecular pathways associated with TP53 expression status in HBV-related HCC by using the ICSNPathway web server based on the result of our previous GWAS.

Materials and methods
=====================

Study population and GWAS data
------------------------------

Our study was approved by the Ethics Committee of the First Affiliated Hospital of Guangxi Medical University with an ethics approval number of 2015 (KY-E-032).[@b15-cmar-10-953] Written informed consent was obtained from all the participants enrolled in the study. The primary GWAS data set was extracted from our previous study.[@b15-cmar-10-953] Clinicopathological characteristics and prognosis of the HBV-related HCC patients, genotyping, quality control, and GWAS analysis methods have been described and published in our earlier article.[@b15-cmar-10-953] A total of 403 patients with serum tests that were HBV surface antigen positive and newly diagnosed with HCC by pathological examination in the First Affiliated Hospital of Guangxi Medical University between 2001 and 2013 were included.[@b15-cmar-10-953] TP53 staining in HCC tumor tissues was detected by immunohistochemistry.[@b15-cmar-10-953] The SNPs were genotyped by an Illumina Human Exome BeadChip 12 v1-1 system (Illumina Inc, San Diego, CA, USA). Quality control standards were set as follows: samples were excluded if they had 1) an overall genotyping rate of \<95%; 2) ambiguous gender; 3) genome-wide identity by-descent \>0.1875; 4) outliers in principal component analysis (PCA) for ancestry and population stratification. SNPs had to meet the following criteria: 1) a call rate of \>95%; 2) a Hardy--Weinberg equilibrium *P*\>1×10^−6^; 3) a minor allele frequency \>0.01.[@b15-cmar-10-953] PCA for ancestry and population stratification suggest that no or mild population stratification was found in the current study population, and similar results were observed in our previous study.[@b15-cmar-10-953] A total of 387 patients with 28,952 SNPs passed the quality control filters and were included in further investigations.

Identification of candidate SNPs and pathways
---------------------------------------------

The ICSNPathway (<http://icsnpathway.psych.ac.cn>, accessed February 20, 2017) web server contains a two-stage analysis: 1) preselect candidate SNPs by LD analysis and functional SNP annotation based on the most significant SNPs and 2) annotate the biological mechanisms for the preselected candidate SNPs by using PBA.[@b14-cmar-10-953] A complete list of GWAS SNP *P*-values was input for ICSNPathway analysis. The parameters used in the ICSNPathway were 1) threshold to specify the most significant SNPs: *P*-value \<1×10^−2^; 2) Hap-Map population: Han Chinese in Beijing, China; 3) LD cut-off: *r*^2^\>0.8; 4) distance for searching LD neighborhoods: 200 kb; 5) rule of mapping SNPs to genes: 500 kb upstream and downstream of gene; 6) pathway/gene set database: Kyoto Encyclopedia of Genes and Genomes; 7) number of genes in each pathway/gene set: minimum 5 and maximum 100; and 8) false discovery rate cutoff for PBA: 0.1.

Association analysis
--------------------

Based on the results of the ICSNPathway analysis, haplotype analysis among the candidate SNPs was calculated using Haploview version 4.2 (Broad Institute of MIT and Harvard, Cambridge, MA, USA).[@b16-cmar-10-953] Regional LD plots of the candidate SNPs were generated by SNP Annotation and Proxy Search (SNAP) (<http://archive.broadinstitute.org/mpg/snap>, accessed February 20, 2017), a tool used for the identification and annotation of proxy SNPs using HapMap.[@b17-cmar-10-953] Genotype and haplotype distribution of the candidate SNPs in different TP53 expression status groups were determined using a binary logistic regression model. Co-expression analysis of the *TP53* gene and the genes of candidate SNPs was performed using GSE14520, a Chinese HBV-related HCC mRNA expression chip data set obtained from Gene Expression Omnibus (<https://www.ncbi.nlm.nih.gov/geo>, accessed February 20, 2017).[@b18-cmar-10-953],[@b19-cmar-10-953] In order to eliminate the batch effect of the expression chip, we only included the Affymetrix HT Human Genome U133A Array data set (Thermo Fisher Scientific, Waltham, MA, USA) of GSE14520 in the co-expression analysis. Gene Multiple Association Network Integration Algorithm[@b20-cmar-10-953],[@b21-cmar-10-953] (GeneMANIA; <http://genemania.org>, accessed February 20, 2017) and Search Tool for the Retrieval of Interacting Genes/Proteins[@b22-cmar-10-953],[@b23-cmar-10-953] (STRING; <http://string.embl.de/>, accessed February 20, 2017) web servers were used for investigating the gene--gene and protein--protein interactions (PPIs) among genes of the candidate SNPs, respectively.

Survival analysis
-----------------

We further analyzed the association of the candidate SNPs and clinical outcomes. The TP53 expression status and the candidate SNP interactions were analyzed using a joint effects survival analysis. In addition, we also analyzed haplotypes of the candidate SNPs.

Statistical analysis
--------------------

Pearson correlation coefficient was used to assess co-expression correlation. The odds ratio (OR) and the corresponding 95% confidence interval (CI) of the binary logistic regression model were used to estimate the relative risk of TP53 expression status in HBV-related HCC. Univariate analysis between clinical features and overall survival (OS) were studied using the Kaplan--Meier method with the log-rank test. Cox proportional hazards regression analysis was used to calculate the crude and adjusted hazard ratio (HR) and 95% CI in univariate and multivariate analyses, with adjustment for age, gender, race, body mass index (BMI), smoking status, drinking status, Barcelona Clinic Liver Cancer (BCLC) stage, cirrhosis, radical resection, antiviral therapy, status of tumor capsule, regional invasion, and portal vein tumor thrombus (PVTT). A value of *P*\<0.05 was considered statistically significant. All the statistical analyses were conducted with SPSS version 20.0 software (IBM Corporation, Armonk, NY, USA).

Results
=======

Candidate SNPs and pathways
---------------------------

Using the *P*-values of the 28,952 GWAS SNPs as input data, the ICSNPathway identified 18 SNPs as candidate SNPs ([Table 1](#t1-cmar-10-953){ref-type="table"}) and 10 pathways as candidate pathways ([Table 2](#t2-cmar-10-953){ref-type="table"}) that were associated with TP53 expression status in HBV-related HCC. All of the candidate SNPs were non-synonymous coding SNPs, and the alteration of four SNPs (desmoglein 3 \[*DSG3*\]-rs16961975, keratin 35 (*KRT35)*-rs2071601, *KRT35*-rs743686, and keratin 36 (*KRT36*)-rs2301354) was deleterious. The strongest mechanism involved the modulation of major histocompatibility complex, class II, DP beta 1 (human leukocyte antigen \[*HLA*\]-*DPB1*-rs1042153), major histocompatibility complex, class II, DQ beta 1 (*HLA-DQB1*-rs1130399, *HLA-DQB1*-rs1049056, *HLA-DQB1*-rs1049059, and *HLA-DQB1*-rs1049060) and major histocompatibility complex, class II, DR beta 1 (*HLA-DRB1*-rs35445101), consequently affecting their regulatory roles in all the candidate pathways except the hematopoietic cell lineage pathway. The second strongest hypothetical biological mechanism was that SNPs of major histocompatibility complex, class I, C (*HLA-C*-rs1131096 and *HLA-C*-rs1130838) influence the regulatory role of cell adhesion molecules (CAMs), autoimmune thyroid disease, allograft rejection, antigen processing and presentation, type I diabetes mellitus, and graft-versus-host disease pathways. Other multiple mechanisms presented in [Tables 1](#t1-cmar-10-953){ref-type="table"} and [2](#t2-cmar-10-953){ref-type="table"} indicated that alterations in candidate SNPs of collagen type VI alpha 3 chain (*COL6A3*)-rs111231885 and *COL6A3*-rs113155945, desmoglein 3 (*DSG3*)-rs16961975, keratin 32 (*KRT32*)-rs3744786), keratin 35 (*KRT35*)-rs2071601 and *KRT35*-rs743686, and keratin 36 (*KRT36*)-rs2301354 affect their regulatory roles in cell communication, whereas legumain (*LGMN*)-rs118128989 alterations affected the antigen processing and presentation pathway and interleukin 6 receptor (*IL6R*)-rs2228145, interleukin 7 receptor (*IL7R*)-rs6897932 alterations affected the hematopoietic cell lineage pathway.

Association analysis
--------------------

In the output of candidate SNPs, *KRT32*-rs3744786 and *KRT35*-rs2071601 were not present in the original GWAS result. So, only 16 candidate SNPs and their corresponding genes were included in further association and survival analysis. Four haplotype blocks were detected in the haplotypes analysis (block 1 pairwise *r*^2^=0.992, constituted by *HLA-C*-rs1130838 and *HLA-C*-rs1131096; block 2 pairwise *r*^2^=0.121--1.0, constituted by *HLA-DRB1*-rs35445101, *HLA-DQB1*-rs1130399, *HLA-DQB1*-rs1049060, *HLA-DQB1*-rs1049059, and *HLA-DQB1*-rs1049056; block 3 pairwise *r*^2^=0.973, constituted by *KRT35*-rs743686 and *KRT36*-rs2301354; block 4 pairwise *r*^2^=0.755, constituted by *COL6A3*-rs111231885 and *COL6A3*-rs113155945; [Figure 1A](#f1-cmar-10-953){ref-type="fig"}). Distribution of candidate SNPs in different TP53 expression status patients is shown in [Table S1](http://www.dovepress.com/get_supplementary_file.php%3Ff%3D163209.xlsx). After adjusting for age, gender, race, BMI, smoking status, drinking status, BCLC stage, cirrhosis, radical resection, antiviral therapy, status of tumor capsule, regional invasion, and PVTT, all the SNPs were significantly associated with TP53 expression status in HBV-related HCC. Association analysis in four haplotypes demonstrated that GT in block 1, AGTCC and GATCC/other haplotypes in block 2, GA/other haplotypes in block 3, and TT/other haplotypes in block 4 had significantly decreased risk of TP53 expression status in HBV-related HCC, compared to patients with TC, AGAGA, AG, and CC ([Table 3](#t3-cmar-10-953){ref-type="table"}), respectively.

Co-expression analysis in HBV-related HCC expression profile data set from the GSE14520 cohort revealed that the *TP53* gene has a significantly weak negative correlation with *HLA-C* (*r*=−0.322, *P*\<0.001), *IL6R* (*r*=−0.132, *P*=0.007), and *KRT36* (*r*=−0.186, *P*\<0.001), whereas it had a positive correlation with *COL6A3* (*r*=0.238, *P*\<0.001), *HLA-DPB1* (*r*=0.115, *P*=0.018), *HLA-DQB1* (*r*=0.176, *P*=0.0003), and *LGMN* (*r*=0.157, *P*=0.001) at the mRNA level in HBV-related HCC of GSE14520; the co-expression heat map is shown in [Figure 1B](#f1-cmar-10-953){ref-type="fig"}. The remaining genes were not significantly correlated with *TP53* at the mRNA level. Gene and gene co-expression interaction networks constructed by GeneMANIA demonstrated that all the genes of the candidate SNPs exist in a complex gene--gene co-expression interaction network and are directly or indirectly associated with *TP53* ([Figure 2A](#f2-cmar-10-953){ref-type="fig"}). In addition, PPIs determined experimentally and constructed by STRING showed that HLA-DQB1, HLA-C, KRT35, IL7R, and LGMN were associated with TP53 through ubiquitin C (UBC) ([Figure 2B](#f2-cmar-10-953){ref-type="fig"}).

Detailed regional LD plots of the four haplotype blocks of the candidate SNPs were generated by SNAP. Regional LD plots for four SNPs of HLA-DQB1 in block 2 are shown in [Figure 3A--D](#f3-cmar-10-953){ref-type="fig"}, whereas the regional LD plot of *HLA-DRB1*-rs35445101 in block 2 was not available on the SNAP website. Regional LD plots of block 3 ([Figure 4A, B](#f4-cmar-10-953){ref-type="fig"}) and block 4 ([Figure 4C, D](#f4-cmar-10-953){ref-type="fig"}) are shown in [Figure 4](#f4-cmar-10-953){ref-type="fig"}, whereas the regional LD plot for block 1 of *HLA-C*-rs1131096 and *HLA-C*-rs1130838 was not available on the SNAP website. Regional LD plot for these SNPs indicated that there were strong LD loci of these blocks detectable in the region nearby them.

Survival analysis
-----------------

Survival analysis was used to further investigate the associations between the candidate SNPs and haplotypes with HBV-related HCC prognosis. Clinicopathological characteristics and prognosis information of patients with HBV-related HCC have been described and published in an earlier article[@b15-cmar-10-953] and shown in [Table 4](#t4-cmar-10-953){ref-type="table"}. Survival analysis of *COL6A3*-rs111231885 showed that patients with the T allele had a shorter median survival time (MST) than those with the C allele (51 vs 33 months for CC vs TT/TC, log-rank *P*=0.012; [Table S2](http://www.dovepress.com/get_supplementary_file.php%3Ff%3D163209.xlsx)). After adjusting for age, gender, race, BMI, smoking status, drinking status, BCLC stage, cirrhosis, radical resection, antiviral therapy, status of tumor capsule, regional invasion, and PVTT in the Cox proportional hazards regression model, patients with the T allele had a significantly increased risk of death compared to those with the C allele (adjusted *P*=0.043, HR=1.64, 95% CI=1.015--2.647; [Table S2](http://www.dovepress.com/get_supplementary_file.php%3Ff%3D163209.xlsx)). Similar results were also observed with *COL6A3*-rs113155945; patients with the TT genotype had a significantly increased risk of death compared to the CC genotype (adjusted *P*=0.047, HR=4.281, 95% CI=1.017--18.022; [Table S2](http://www.dovepress.com/get_supplementary_file.php%3Ff%3D163209.xlsx)). In addition, joint effects analysis was also used to explore the SNPs and TP53 interaction in HBV-related HCC prognosis. TP53-negative patients with the *COL6A3*-rs111231885 T allele carriers had a significantly increased risk of death (adjusted *P*=0.034, HR=1.994, 95% CI=1.052--3.778; [Table S3](http://www.dovepress.com/get_supplementary_file.php%3Ff%3D163209.xlsx)) and a poor clinical outcome (MST: 33 vs 68 months for TT/TC vs CC, log-rank *P*=0.031; [Table S3](http://www.dovepress.com/get_supplementary_file.php%3Ff%3D163209.xlsx)) in HBV-related HCC, compared to TP53-negative patients with C allele carriers. No other genotypes were significantly associated with OS in single and joint effects analysis.

Survival analysis for haplotypes of candidate SNPs is shown in [Figure 5A--D](#f5-cmar-10-953){ref-type="fig"}, and indicated that patients with TT/other haplotypes in block 4 had a significantly shorter OS (MST: 33 vs 51 months for TT/other haplotypes vs CC, log-rank *P*=0.019; [Table 5](#t5-cmar-10-953){ref-type="table"}, [Figure 5D](#f5-cmar-10-953){ref-type="fig"}). Multivariate analyses of the Cox proportional hazards regression model suggest that patients with TT/other haplotypes in block 4 had increased risk of death in HBV-related HCC (adjusted *P*=0.07, HR=1.450, 95% CI=0.970--2.167; [Table 5](#t5-cmar-10-953){ref-type="table"}), with a critically significant *P*-value, compared to patients with CC haplotypes. Joint effects analysis ([Figure 6A--D](#f6-cmar-10-953){ref-type="fig"}) indicated that TP53-negative patients with TT/other haplotypes in block 4 had a significantly poor prognosis (MST: 33 vs 68 months for TT/other haplotypes vs CC haplotypes, log-rank *P*=0.047; [Table 6](#t6-cmar-10-953){ref-type="table"}, [Figure 6D](#f6-cmar-10-953){ref-type="fig"}) and increased risk of death in HBV-related HCC (adjusted *P*=0.047, HR=1.713, 95% CI =1.006--2.918; [Table 6](#t6-cmar-10-953){ref-type="table"}), compared to TP53-negative patients with CC haplotypes. No other haplotypes were significantly associated with OS in single or joint effects analysis.

Discussion
==========

The GWAS approach is increasingly being used to discover the association between genes and disease. However, most GWAS have focused on SNPs with high statistical significance, whereas many other SNPs have received little attention and the full potential of these data have not been fully exploited.[@b24-cmar-10-953],[@b25-cmar-10-953] Therefore, it is necessary to perform in-depth data mining with GWAS results. Genome-wide pathway analysis can investigate the GWAS SNPs through a SNP→gene→pathway approach to discover the overrepresented pathways in the GWAS data, which would consider rare variants, multi-omics, and interactions. In the current study, ICSNPathway analysis identified 18 candidate SNPs and 10 candidate pathways that are associated with TP53 expression status in HBV-related HCC. Five hypothetical biological mechanisms can be obtained from ICSNPathway analysis.

The strongest hypothetical biological mechanism found that the candidate SNPs of *HLA-DPB1*, *HLA-DQB1*, and *HLA-DRB1* affected their regulatory roles in all the candidate pathways except hematopoietic cell lineage pathway. The major histocompatibility complex class II molecule is a heterodimer consisting of an alpha (DQA) and a beta chain (DQB), both anchored in the membrane. Previous studies have demonstrated that *HLA-DPB1* polymorphisms were significantly associated with the risk of HBV infection susceptibility,[@b26-cmar-10-953],[@b27-cmar-10-953] whereas the distribution of the SNPs genotype frequencies was similar in HCC and chronic hepatitis B patients.[@b26-cmar-10-953],[@b28-cmar-10-953] A case--control study that compared persistence and natural clearance of HBV infection in a population indicated that the *HLA-DPB1*-rs9277535 A allele has a major effect on the risk of persistent HBV infection.[@b29-cmar-10-953] Subsequently, another study also reported that *HLA-DPB1*-rs9277535 was significantly related to HBV infection risks and increased HBV clearance possibility in a dose-dependent manner.[@b30-cmar-10-953] Furthermore, the polymorphisms of another HLA class II molecule, *HLA-DQB1*, were also associated with the development of chronic HBV infection and liver cirrhosis,[@b31-cmar-10-953] as well as the risk factor of HCC.[@b32-cmar-10-953],[@b33-cmar-10-953] In addition, our previous study also showed that *HLA-DQB1* polymorphisms have a prognosis predictive value in HBV-related HCC patients undergoing hepatic resection.[@b34-cmar-10-953] Similar genetic susceptibility research on *HLA-DRB1* also demonstrated that polymorphisms in the *HLA-DRB1* gene were significantly associated with HCC risk, HBV infection, and progression from CHB to HCC.[@b35-cmar-10-953]--[@b38-cmar-10-953]

The second strongest mechanism was that a candidate SNP of *HLA-C*-rs1131096 and *HLA-C*-rs1130838 influenced the regulatory role of CAMs, autoimmune thyroid disease, allograft rejection, antigen processing and presentation, type I diabetes mellitus, and graft-versus-host disease pathways. HLA-C belongs to the HLA class I heavy chain paralogues and its genetic variation can influence the risk of HBV-related HCC development;[@b39-cmar-10-953] furthermore, HLA-C\*15 is also an important host immunogenetic factor that negatively associates with hepatitis C virus viral load in chronic hepatitis C patients.[@b40-cmar-10-953]

Studies of major histocompatibility complex class I and II gene polymorphisms demonstrate a risk factor for hepatitis virus and HCC. In the current study, our findings suggest that genetic variation in *HLA-DPB1*, *HLA-DQB1*, *HLA-DRB1*, and *HLA-C* were associated with TP53 expression status in HBV-related HCC. These results contribute to a better understanding of the heritability of *HLA-DPB1*, *HLA-DQB1*, *HLA-DRB1*, and *HLA-C* in HBV-related HCC and subsequently provide hypotheses to clarify their potential mechanisms in HBV and HCC genetic susceptibility.

In the remaining genes with candidate SNPs, we only found that *IL6R* and *IL7R* were associated with HCC among the previous studies, whereas associations between the other genes and human HCC have not been reported. IL6R encodes a subunit of the *IL6R* complex, and its dysregulation is related to the pathogenesis of many diseases, including cancer. A study by Deng et al revealed that the *IL6R*-rs6684439 T allele is associated with a lower susceptibility of HBV-related HCC in the Guangxi population,[@b41-cmar-10-953] whereas miR-451 plays a suppressive role in tumor angiogenesis via the regulation of the IL6R-signal transducer and activator of transcription 3-vascular endothelial growth factor signaling pathway.[@b42-cmar-10-953] Research by Midorikawa et al confirms that IL7R is downregulated in well-differentiated tumor tissue in HCC and can serve as a predictor gene of HCC dedifferentiation.[@b43-cmar-10-953] Our results contribute to a better understanding of genes associated with different HBV-related HCC subgroups.

Our association analysis demonstrated that seven genes with candidate SNPs were correlated to *TP53* at the HBV-related HCC mRNA level, whereas PPI networks showed that five genes with candidate SNPs were associated with TP53 via UBC through experiments. However, the GeneMANIA gene--gene interaction networks showed complex co-expression networks among those genes, and all genes were directly or indirectly related to the *TP53* gene. In the present study, we confirmed that *LGMN* and *TP53* are positively correlated at the mRNA level in HBV-related HCC based on the GSE14520 data set, and our bioinformatics analysis by GeneMANIA also suggests that *LGMN* and *TP53* were co-expressed via the *TAP1* gene, whereas *LGMN* was also related to *TP53* via the *UBC* gene in the PPI networks that were constructed by STRING. A study by Murthy et al has reported that *LGMN* was significantly upregulated in tumor tissue and its low expression showed a better prognosis in colorectal cancer (CRC); meanwhile, it has a positive correlation with *TP53*.[@b44-cmar-10-953] *LGMN* expression and its enzyme activity can also be regulated by *TP53*, and knockdown experiments suggest that *LGMN* and *TP53* have a positive correlation in HCT116 cells.[@b45-cmar-10-953] Our bioinformatics analysis also suggests that IL7R is associated with TP53 in GeneMANIA and PPI networks, and *IL7*/*IL7R* prevents apoptosis by regulating *bcl-2* expression and the *TP53* pathway in A549 and human bronchial epithelial cells.[@b46-cmar-10-953] Among the 10 candidate pathways, CAMs and cell communication pathways were the most common hypothetical biological mechanisms that involved the majority of candidate SNPs. CAMs play an important role in cell communication[@b47-cmar-10-953] and are associated with HCC diagnosis and survival prediction.[@b48-cmar-10-953],[@b49-cmar-10-953] Our findings suggest a novel hypothetical biological mechanism between CAMs and TP53 expression status in HBV-related HCC.

Survival analysis in the current study indicates that the C allele of *COL6A3*-rs111231885 and *COL6A3*-rs113155945, and *COL6A3* block 4 CC haplotypes with TP53 negative status significantly decrease the risk of death in HBV-related HCC patients after hepatectomy. Previous studies have confirmed that high *COL6A3* expression was significantly associated with poor prognosis and its mutation can be used for survival prediction in CRC.[@b50-cmar-10-953],[@b51-cmar-10-953] Furthermore, *COL6A3* was markedly upregulated in the tumor tissue of gastric cancer,[@b52-cmar-10-953],[@b53-cmar-10-953] pancreatic cancer,[@b54-cmar-10-953],[@b55-cmar-10-953] and CRC[@b50-cmar-10-953],[@b56-cmar-10-953] and can serve as a potential diagnostic biomarker in these cancers. This evidence suggests that *COL6A3* may be a potential diagnosis and prognosis marker in CRC and may serve as an oncogene of CRC. Our findings demonstrate that several SNPs of *COL6A3* have a prediction value for HBV-related HCC prognosis and provide insight into the clinical utility of HBV-related HCC prognosis. Once validated, *COL6A3* may be used for prognosis prediction and decision-making in HCC management.

There were limitations in our study that need to be recognized. First, our study evaluates the association between TP53 expression status and candidate SNPs using the GWAS approach, and validates the association between the genes of the candidate SNPs and *TP53* using the Gene Expression Omnibus data set, GeneMANIA, and STRING bioinformatics tools that lack confirmation by in vivo and in vitro experiments. Second, all patients in the present study were exclusively from a Guangxi population of HBV-related HCC; therefore, in order to generalize our findings, additional external validation in cohorts from other ethnic populations is necessary to confirm our results.

Despite these limitations, our study is the first to explore the association between the SNPs and molecular pathways associated with TP53 expression status in HBV-related HCC by using the genome-wide association pathway analysis approach, and that might have etiology or clinical implications.

Conclusion
==========

Genome-wide association pathway analysis in the current study identified 18 candidate SNPs and 10 candidate pathways that are associated with TP53 expression status in HBV-related HCC and generated five novel SNP-to-gene to pathway hypotheses. These results contribute to a better understanding of the heritability of HBV-related HCC in different TP53 expression subgroups and provide evidence for personalized treatment strategies of different TP53 expression subgroups in HBV-related HCC patients. Additional in vivo and in vitro experimental studies will be necessary to elucidate the role of these pathways in different TP53 expression subgroups of HBV-related HCC. Among these candidate SNPs, the C allele of *COL6A3*-rs111231885 and *COL6A3*-rs113155945, and *COL6A3* block 4 CC haplotypes with TP53 negative status may have protective effects in HBV-related HCC patients after hepatectomy and can serve as a potential prognostic biomarker. Further well-designed and larger sample size studies are needed to validate the associations between *COL6A3* genetic variation and HBV-related HCC prognosis.
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![Haplotype association of the candidate SNPs and co-expression heat map for the *TP53* gene and corresponding genes of the candidate SNPs.\
**Notes:** (**A**) Patterns of LD plots for 16 candidate SNPs. (**B**) Co-expression heat map between TP53 and corresponding genes of the candidate SNPs.\
**Abbreviations:** SNP, single nucleotide polymorphism; TP53, tumor protein p53; LD, linkage disequilibrium.](cmar-10-953Fig1){#f1-cmar-10-953}

![Gene--gene and protein--protein interaction networks.\
**Notes:** (**A**) Gene--gene interaction networks constructed by GeneMANIA. (**B**) Protein--protein interaction networks constructed by STRING.\
**Abbreviations:** GeneMANIA, Gene Multiple Association Network Integration Algorithm; STRING, Search Tool for the Retrieval of Interacting Genes/Proteins; TP53, tumor protein p53; UBC, ubiquitin C; *HLA-DPB1*, major histocompatibility complex, class II, DP beta 1; *HLA-DQB1*, major histocompatibility complex, class II, DQ beta 1; *HLA-DRB1*, major histocompatibility complex, class II, DR beta 1; *HLA-C*, major histocompatibility complex, class I, C; *COL6A3*, collagen type VI alpha 3 chain; *DSG3*, desmoglein 3; *KRT32*, keratin 32; *KRT35*, keratin 35; *KRT36*, keratin 36; *LGMN*, legumain; *IL6R*, interleukin 6 receptor; *IL7R*, interleukin 7 receptor.](cmar-10-953Fig2){#f2-cmar-10-953}

![Regional LD plots of block 2 (*HLA-DQB1*).\
**Notes:** Regional LD plots of (**A**) *HLA-DQB1*-rs1049056, (**B**) *HLA-DQB1*-rs1049059, (**C**) *HLA-DQB1*-rs1049060, and (**D**) *HLA-DQB1*-rs1130399.\
**Abbreviations:** LD, linkage disequilibrium; HLA-DQB1, major histocompatibility complex, class II, DQ beta 1; CHB, chronic hepatitis B.](cmar-10-953Fig3){#f3-cmar-10-953}

![Regional LD plots of block 3 (*KRT35* and *KRT36*) and block 4 (*COL6A3*).\
**Notes:** Regional LD plots of (**A**) *KRT35*-rs743686, (**B**) *KRT36*-rs2301354, (**C**) *COL6A3*-rs111231885, and (**D**) *COL6A3*-rs113155945.\
**Abbreviations:** LD, linkage disequilibrium; KRT35, keratin 35; KRT36, keratin 36; COL6A3, collagen type VI alpha 3 chain.](cmar-10-953Fig4){#f4-cmar-10-953}

![Survival curves of different haplotypes.\
**Notes:** OS stratified by (**A**) block 1 haplotypes, (**B**) block 2 haplotypes, (**C**) block 3 haplotypes, (**D**) block 4 haplotypes.\
**Abbreviations:** OS, overall survival.](cmar-10-953Fig5){#f5-cmar-10-953}

![Joint effects survival analysis of different haplotypes and TP53 expression status.\
**Notes:** OS stratified by (**A**) block 1 haplotypes and TP53 expression status, (**B**) block 2 haplotypes and TP53 expression status, (**C**) block 3 haplotypes and TP53 expression status, (**D**) block 4 haplotypes and TP53 expression status.\
**Abbreviations:** OS, overall survival; TP53, tumor protein p53.](cmar-10-953Fig6){#f6-cmar-10-953}

###### 

Candidate SNPs identified from ICSNPathway analysis

  Candidate SNP   Functional class                      Gene         Candidate pathway[a](#tfn1-cmar-10-953){ref-type="table-fn"}   −log10(*P*)[b](#tfn2-cmar-10-953){ref-type="table-fn"}   In LD with    *r*^2^   D'      −log10(*P*)[c](#tfn3-cmar-10-953){ref-type="table-fn"} in original GWAS
  --------------- ------------------------------------- ------------ -------------------------------------------------------------- -------------------------------------------------------- ------------- -------- ------- -------------------------------------------------------------------------
  rs1042153       non_synonymous_coding                 *HLA-DPB1*   1,2,3,4,5,7,9,10                                               2.45                                                     rs1042153     --       --      2.45
  rs1130399       non_synonymous_coding                 *HLA-DQB1*   1,2,3,4,5,7,9,10                                               3.153                                                    rs1130399     --       --      3.153
  rs1049056       non_synonymous_coding                 *HLA-DQB1*   1,2,3,4,5,7,9,10                                               2.433                                                    rs1049056     --       --      2.433
  rs1049059       non_synonymous_coding                 *HLA-DQB1*   1,2,3,4,5,7,9,10                                               2.357                                                    rs1049059     --       --      2.357
  rs1049060       non_synonymous_coding                 *HLA-DQB1*   1,2,3,4,5,7,9,10                                               2.467                                                    rs1049060     --       --      2.467
  rs35445101      non_synonymous_coding                 *HLA-DRB1*   1,2,3,4,5,7,8,9,10                                             3.591                                                    rs35445101    --       --      3.591
  rs1131096       non_synonymous_coding                 *HLA-C*      3,4,5,7,9,10                                                   2.097                                                    rs1131096     --       --      2.097
  rs1130838       non_synonymous_coding                 *HLA-C*      3,4,5,7,9,10                                                   2.267                                                    rs1130838     --       --      2.267
  rs111231885     non_synonymous_coding                 *COL6A3*     6                                                              2.541                                                    rs111231885   --       --      2.541
  rs113155945     non_synonymous_coding                 *COL6A3*     6                                                              2.044                                                    rs113155945   --       --      2.044
  rs16961975      non_synonymous_coding (deleterious)   *DSG3*       6                                                              2.12                                                     rs16961975    --       --      2.12
  rs3744786       non_synonymous_coding                 *KRT32*      6                                                              --                                                       rs2301354     0.847    0.945   3.583
  rs2071601       non_synonymous_coding (deleterious)   *KRT35*      6                                                              --                                                       rs2301354     0.901    1       3.583
  rs743686        non_synonymous_coding (deleterious)   *KRT35*      6                                                              3.209                                                    rs743686      --       --      3.209
  rs2301354       non_synonymous_coding (deleterious)   *KRT36*      6                                                              3.583                                                    rs2301354     --       --      3.583
  rs118128989     non_synonymous_coding                 *LGMN*       7                                                              2.084                                                    rs118128989   --       --      2.084
  rs2228145       non_synonymous_coding                 *IL6R*       8                                                              2.081                                                    rs2228145     --       --      2.081
  rs6897932       non_synonymous_coding                 *IL7R*       8                                                              2.004                                                    rs6897932     --       --      2.004

**Notes:**

The number indicates the index of pathways (listed in [Table 2](#t2-cmar-10-953){ref-type="table"}), which are ranked by their statistical significance (FDR).

−log~10~(*P*) for candidate SNP in original GWAS. "--" denotes that this SNP is not represented in the original GWAS.

−log~10~(*P*) for the SNP (which candidate SNP is in LD with) in original GWAS.

**Abbreviations:** SNP, single nucleotide polymorphism; ICSNPathway, Identify candidate Causal SNPs and Pathways; LD, linkage disequilibrium; GWAS, genome-wide association studies; *HLA-DPB1*, major histocompatibility complex, class II, DP beta 1; *HLA-DQB1*, major histocompatibility complex, class II, DQ beta 1; *HLA-DRB1*, major histocompatibility complex, class II, DR beta 1; *HLA-C*, major histocompatibility complex, class I, C; *COL6A3*, collagen type VI alpha 3 chain; *DSG3*, desmoglein 3; *KRT32*, keratin 32; *KRT35*, keratin 35; *KRT36*, keratin 36; *LGMN*, legumain; *IL6R*, interleukin 6 receptor; *IL7R*, interleukin 7 receptor; FDR, false discovery rate.

###### 

Candidate pathways identified from ICSNPathway analysis

  Index   Candidate pathway   Description                           Nominal *P*-value   FDR
  ------- ------------------- ------------------------------------- ------------------- -------
  1       hsa05310            Asthma                                0.005               0.026
  2       hsa05322            Systemic lupus erythematosus          0.005               0.026
  3       hsa04514            CAMs                                  0.034               0.056
  4       hsa05320            Autoimmune thyroid disease            0.028               0.058
  5       hsa05330            Allograft rejection                   0.028               0.058
  6       hsa01430            Cell communication                    0.024               0.058
  7       hsa04612            Antigen processing and presentation   0.041               0.06
  8       hsa04640            Hematopoietic cell lineage            0.009               0.069
  9       hsa04940            Type I diabetes mellitus              0.032               0.077
  10      hsa05332            Graft-versus-host disease             0.032               0.077

**Abbreviations:** FDR, false discovery rate; CAMs, cell adhesion molecules; ICSNPathway, Identify candidate Causal SNPs and Pathways.

###### 

Haplotype distribution of the candidate SNPs in patients with different TP53 expression status

  Haplotypes               TP53 negative (2n=308)   TP53 positive (2n=466)   Crude OR (95% CI)      Crude *P*-value   Adjusted OR (95% CI)   Adjusted *P*-value[a](#tfn6-cmar-10-953){ref-type="table-fn"}
  ------------------------ ------------------------ ------------------------ ---------------------- ----------------- ---------------------- ---------------------------------------------------------------
  **Block 1**                                                                                                                                
  TC                       229                      387                      1                                        1                      
  GT                       79                       79                       0.592 (0.416--0.841)   0.003             0.622 (0.432--0.895)   0.011
  **Block 2**                                                                                                                                
  AGAGA                    118                      238                      1                                        1                      
  AGTCC                    116                      167                      0.714 (0.516--0.987)   0.041             0.696 (0.494--0.980)   0.038
  GATCC+other haplotypes   74                       61                       0.409 (0.273--0.612)   \<0.001           0.395 (0.259--0.603)   \<0.001
  **Block 3**                                                                                                                                
  AG                       156                      291                      1                                        1                      
  GA+other haplotypes      152                      175                      0.617 (0.461--0.826)   0.001             0.582 (0.427--0.792)   0.001
  **Block 4**                                                                                                                                
  CC                       279                      446                      1                                        1                      
  TT+other                 29                       20                       0.431 (0.239--0.777)   0.005             0.376 (0.201--0.703)   0.002
  haplotypes                                                                                                                                 

**Notes:**

Adjusted for age, gender, race, body mass index, smoking status, drinking status, BCLC stage, cirrhosis, radical resection, antiviral therapy, status of tumor capsule, regional invasion, and PVTT.

**Abbreviations:** SNP, single nucleotide polymorphism; TP53, tumor protein p53; BCLC, Barcelona Clinic Liver Cancer; PVTT, portal vein tumor thrombus.

###### 

Clinicopathological characteristics of patients with HBV-related HCC after data quality control

  Variable                                                          GWAS   Survival analysis                                                                    
  ----------------------------------------------------------------- ------ ------------------- ---------------------- ------- ----- ---- ---------------------- ---------
  Age (years)                                                                                                                                                   0.313
   ≤60                                                              133    211                 1                              344   51   1                      
   \>60                                                             21     22                  0.66 (0.35--1.247)     0.201   43    41   1.268 (0.795--2.023)   
  Sex                                                                                                                                                           0.563
   Male                                                             141    207                 1                              348   48   1                      
   Female                                                           13     26                  0.734 (0.365--1.477)   0.386   39    42   0.856 (0.504--1.455)   
  Race                                                                                                                                                          0.837
   Han                                                              103    142                 1                              245   47   1                      
   Minority                                                         51     91                  1.294 (0.845--1.983)   0.236   142   50   0.968 (0.711--1.318)   
  BMI                                                                                                                                                           0.933
   ≤25                                                              121    181                 1                              302   48   1                      
   \>25                                                             33     52                  1.053 (0.643--1.725)   0.836   85    47   0.985 (0.694--1.399)   
  Smoking status                                                                                                                                                0.054
   None                                                             97     147                 1                              244   61   1                      
   Ever                                                             57     86                  0.996 (0.653--1.518)   0.984   143   39   1.342 (0.992--1.816)   
  Drinking status                                                                                                                                               0.153
   None                                                             91     134                 1                              225   51   1                      
   Ever                                                             63     99                  1.067 (0.706--1.613)   0.758   162   41   1.239 (0.921--1.666)   
  Child--Pugh[a](#tfn8-cmar-10-953){ref-type="table-fn"}                                                                                                        0.009
   A                                                                116    189                 1                              305   51   1                      
   B                                                                28     30                  0.658 (0.374--1.156)   0.146   58    31   1.665 (1.131--2.452)   
  Cirrhosis                                                                                                                                                     0.117
   No                                                               12     27                  1                              39    88   1                      
   Yes                                                              142    206                 0.645 (0.316--1.315)   0.228   348   48   1.503 (0.897--2.518)   
  Radical resection[b](#tfn9-cmar-10-953){ref-type="table-fn"}                                                                                                  0.095
   Yes                                                              82     133                 1                              215   71   1                      
   None                                                             67     94                  0.865 (0.57--1.313)    0.496   161   41   1.286 (0.955--1.733)   
  Portal hypertension[c](#tfn10-cmar-10-953){ref-type="table-fn"}                                                                                               0.347
   No                                                               69     124                 1                              193   52   1                      
   Yes                                                              75     87                  0.645 (0.421--0.989)   0.044   162   42   1.163 (0.847--1.598)   
  Pathological grade[d](#tfn11-cmar-10-953){ref-type="table-fn"}                                                                                                0.665
   Well differentiated                                              14     10                  1                              24    79   1                      
   Moderately differentiated                                        126    190                 2.111 (0.909--4.901)   0.082   316   48   1.350 (0.688--2.648)   
   Poorly differentiated                                            1      10                  14 (1.536--127.621)    0.019   11    NA   1.203 (0.370--3.908)   
  Serum AFP[e](#tfn12-cmar-10-953){ref-type="table-fn"}                                                                                                         0.499
   ≤400 (ng/mL)                                                     87     110                 1                              197   51   1                      
   \>400 (ng/mL)                                                    58     105                 1.432 (0.935--2.193)   0.099   163   43   1.111 (0.817--1.512)   
  Antiviral therapy                                                                                                                                             0.002
   No                                                               95     157                 1                              252   40   1                      
   Yes                                                              59     76                  0.779 (0.51--1.192)    0.25    135   NA   0.574 (0.398--0.828)   
  **Tumor behavior**                                                                                                                                            
  Tumor size                                                                                                                                                    \<0.001
   ≤5 cm                                                            72     85                  1                              157   75   1                      
   \>5 cm                                                           82     148                 1.529 (1.011--2.313)   0.044   230   39   1.757 (1.278--2.415)   
  Tumor number                                                                                                                                                  \<0.001
   Single                                                           111    169                 1                              280   58   1                      
   Multiple                                                         43     64                  0.978 (0.62--1.54)     0.922   107   27   1.788 (1.310--2.439)   
  Status of tumor capsule                                                                                                                                       0.131
   Complete                                                         126    201                 1                              327   50   1                      
   Incomplete                                                       28     32                  0.716 (0.412--1.247)   0.238   60    35   1.335 (0.914--1.949)   
  Regional invasion                                                                                                                                             0.421
   Absence                                                          131    199                 1                              330   51   1                      
   Presence                                                         23     34                  0.973 (0.549--1.726)   0.926   57    40   1.185 (0.781--1.800)   
  BCLC stage                                                                                                                                                    \<0.001
   A                                                                87     129                 1                              216   95   1                      
   B                                                                28     38                  0.915 (0.523--1.6)     0.756   66    39   2.080 (1.395--3.102)   
   C                                                                39     66                  1.141 (0.706--1.845)   0.59    105   27   2.672 (1.919--3.720)   
  PVTT                                                                                                                                                          \<0.001
   No                                                               130    189                 1                              319   73   1                      
   Yes                                                              24     44                  1.261 (0.731--2.175)   0.404   68    27   2.233 (1.615--3.088)   

**Notes:**

Child--Pugh class was unavailable in 24 patients. Information of

radical resection was unavailable in 11 patients,

portal hypertension was unavailable in 32 patients,

pathological diagnosis was unavailable in 36 patients,

serum AFP level was unavailable in 27 patients.

**Abbreviations:** GWAS, genome-wide association study; BMI, body mass index; AFP, α-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; PVTT, portal vein tumor thrombus; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; NA, not applicable; TP53, tumor protein p53; MST, median survival time.

###### 

Survival analysis of different haplotypes

  Haplotypes               Patients (2n=774)   MST (months)   Crude HR (95% CI)      Crude *P*-value   Adjusted HR (95% CI)   Adjusted *P*-value[a](#tfn14-cmar-10-953){ref-type="table-fn"}
  ------------------------ ------------------- -------------- ---------------------- ----------------- ---------------------- ----------------------------------------------------------------
  **Block 1**                                                                                                                 
  TC                       616                 47             1                                        1                      
  GT                       158                 68             0.913 (0.702--1.187)   0.497             0.934 (0.714--1.221)   0.618
  **Block 2**                                                                                                                 
  AGAGA                    356                 51             1                                        1                      
  AGTCC                    283                 48             0.930 (0.735--1.176)   0.544             0.915 (0.717--1.170)   0.48
  GATCC+other haplotypes   135                 41             1.198 (0.909--1.580)   0.199             1.153 (0.867--1.533)   0.327
  **Block 3**                                                                                                                 
  AG                       447                 58             1                                        1                      
  GA+other haplotypes      327                 41             1.132 (0.918--1.396)   0.247             1.121 (0.903--1.392)   0.299
  **Block 4**                                                                                                                 
  CC                       725                 51             1                                        1                      
  TT+other haplotypes      49                  33             1.566 (1.070--2.292)   0.021             1.450 (0.970--2.167)   0.07

**Notes:**

Adjusted for age, gender, race, body mass index, smoking status, drinking status, BCLC stage, cirrhosis, radical resection, antiviral therapy, status of tumor capsule, regional invasion, and PVTT.

**Abbreviations:** BCLC, Barcelona Clinic Liver Cancer; PVTT, portal vein tumor thrombus; MST, median survival time.

###### 

Joint effects survival analysis of different haplotypes and TP53 expression status

  Group       Haplotypes               TP53 status   Patients (2n=774)   MST (months)   Crude HR (95% CI)      Crude *P*-value   Adjusted HR (95% CI)   Adjusted *P*-value[a](#tfn16-cmar-10-953){ref-type="table-fn"}
  ----------- ------------------------ ------------- ------------------- -------------- ---------------------- ----------------- ---------------------- ----------------------------------------------------------------
              **Block 1**                                                                                                                               
  Group 1     TC                       Negative      229                 51             1                                        1                      
  Group 2     TC                       Positive      387                 43             1.107 (0.868--1.413)   0.413             1.104 (0.855--1.425)   0.449
  Group 3     GT                       Negative      79                  68             0.845 (0.567--1.260)   0.409             0.857 (0.570--1.289)   0.459
  Group 4     GT                       Positive      79                  41             1.126 (0.771--1.644)   0.539             1.158 (0.787--1.706)   0.456
              **Block 2**                                                                                                                               
  Group A     AGAGA                    Negative      118                 68             1                                        1                      
  Group B     AGAGA                    Positive      238                 41             1.302 (0.928--1.827)   0.126             1.206 (0.854--1.704)   0.288
  Group C     AGTCC+other haplotypes   Negative      190                 48             1.171 (0.818--1.675)   0.389             1.057 (0.733--1.524)   0.765
  Group D     AGTCC+other haplotypes   Positive      228                 43             1.256 (0.892--1.769)   0.191             1.199 (0.841--1.709)   0.316
              **Block 3**                                                                                                                               
  Group i     AG                       Negative      156                 71             1                                        1                      
  Group ii    AG                       Positive      291                 48             1.243 (0.920--1.678)   0.156             1.329 (0.976--1.811)   0.071
  Group iii   GA+other haplotypes      Negative      152                 45             1.235 (0.875--1.743)   0.23              1.341 (0.943--1.905)   0.102
  Group iv    GA+other haplotypes      Positive      175                 40             1.380 (0.993--1.918)   0.055             1.361 (0.971--1.908)   0.074
              **Block 4**                                                                                                                               
  Group I     CC                       Negative      279                 68             1                                        1                      
  Group II    CC                       Positive      446                 44             1.196 (0.953--1.501)   0.123             1.261 (0.995--1.599)   0.055
  Group III   TT+other haplotypes      Negative      29                  33             1.677 (0.992--2.834)   0.054             1.713 (1.006--2.918)   0.047
  Group IV    TT+other haplotypes      Positive      20                  32             1.855 (1.045--3.294)   0.035             1.651 (0.872--3.126)   0.123

**Notes:**

Adjusted for age, gender, race, body mass index, smoking status, drinking status, BCLC stage, cirrhosis, radical resection, antiviral therapy, status of tumor capsule, regional invasion, and PVTT.

**Abbreviations:** TP53, tumor protein p53; BCLC, Barcelona Clinic Liver Cancer; PVTT, portal vein tumor thrombus; MST, median survival time.
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